Business Description
Incyte Corp
NAICS : 541714
SIC : 8731
ISIN : US45337C1027
Share Class Description:
WBO:INCY: Ordinary SharesTotal Employee Number:
2,844Compare
Compare
Traded in other countries / regions
INCY.USA0J9P.UKICY.GermanyI1NC34.BrazilINCY.Mexico1INCY.ItalyINCY.Austria IPO Date
2017-05-22Description
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 101.85 | |||||
Equity-to-Asset | 0.77 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | 0.02 | |||||
Interest Coverage | 620.56 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 10.56 | |||||
Beneish M-Score | -2.48 | |||||
WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 19.1 | |||||
3-Year EBITDA Growth Rate | 48.5 | |||||
3-Year EPS without NRI Growth Rate | 34.7 | |||||
3-Year FCF Growth Rate | 18.5 | |||||
3-Year Book Growth Rate | 9.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 12.5 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 8.14 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.68 | |||||
Quick Ratio | 3.6 | |||||
Cash Ratio | 2.7 | |||||
Days Inventory | 80.99 | |||||
Days Sales Outstanding | 63.15 | |||||
Days Payable | 189.49 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 3.8 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 92.48 | |||||
Operating Margin % | 27.05 | |||||
Net Margin % | 26.71 | |||||
EBITDA Margin % | 34.9 | |||||
FCF Margin % | 26.42 | |||||
OCF Margin % | 28.2 | |||||
ROE % | 30.75 | |||||
ROA % | 22.23 | |||||
ROIC % | 39.88 | |||||
3-Year ROIIC % | 87.46 | |||||
ROC (Joel Greenblatt) % | 223.45 | |||||
ROCE % | 35.73 | |||||
Years of Profitability over Past 10-Year | 8 | |||||
Moat Score | 7 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 16.75 | |||||
Forward PE Ratio | 10.45 | |||||
PE Ratio without NRI | 15.93 | |||||
Shiller PE Ratio | 66.06 | |||||
Price-to-Owner-Earnings | 21.29 | |||||
PS Ratio | 4.49 | |||||
PB Ratio | 4.22 | |||||
Price-to-Tangible-Book | 4.41 | |||||
Price-to-Free-Cash-Flow | 17.01 | |||||
Price-to-Operating-Cash-Flow | 15.93 | |||||
EV-to-EBIT | 10.89 | |||||
EV-to-Forward-EBIT | 20.34 | |||||
EV-to-EBITDA | 10.33 | |||||
EV-to-Forward-EBITDA | 19.51 | |||||
EV-to-Revenue | 3.61 | |||||
EV-to-Forward-Revenue | 5.23 | |||||
EV-to-FCF | 13.87 | |||||
Price-to-GF-Value | 1.19 | |||||
Price-to-Projected-FCF | 2 | |||||
Price-to-Median-PS-Value | 0.67 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.83 | |||||
Price-to-Graham-Number | 1.77 | |||||
| Price-to-Net-Current-Asset-Value | 6.29 | |||||
| Price-to-Net-Cash | 10.3 | |||||
Earnings Yield (Greenblatt) % | 9.18 | |||||
FCF Yield % | 6.09 | |||||
Forward Rate of Return (Yacktman) % | 22.18 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Incyte Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 4,605.381 | ||
| EPS (TTM) (€) | 6.086 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | -51.37 | ||
| 3-Year Sortino Ratio | -3.46 | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR (€) | - | ||
| 20-Day SMA (€) | 70.36 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 70.36 - 70.36 | ||
| Shares Outstanding (Mil) | 199.78 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Incyte Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Incyte Corp Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-10-28 08:00 | In 110 days | ||
| Third quarter earnings results for 2026 | 2026-10-28 07:00 | In 110 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-28 08:00 | In 18 days | ||
| Second quarter earnings results for 2026 | 2026-07-28 07:00 | In 18 days | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-09 08:40 | 70.36 (+0.00%) | ||
| General meeting for 2026 | 2026-06-08 10:00 | 70.36 (+0.00%) | ||
| Incyte Conference Call and Webcast | 2026-06-08 08:00 | 70.36 (+0.00%) | ||
| Guidance call for 2026 | 2026-05-19 10:30 | 70.36 (+0.00%) | ||
| Guidance call for 2026 | 2026-05-13 13:40 | 70.36 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-04-28 08:00 | 70.36 (+0.00%) |
Show
Entries
Incyte Corp Frequently Asked Questions
What is Incyte Corp(WBO:INCY)'s stock price today?
The current price of WBO:INCY is €70.36. The 52 week high of WBO:INCY is €70.36 and 52 week low is €70.36.
When is next earnings date of Incyte Corp(WBO:INCY)?
The next earnings date of Incyte Corp(WBO:INCY) is 2026-07-28.
Does Incyte Corp(WBO:INCY) pay dividends? If so, how much?
Incyte Corp(WBO:INCY) does not pay dividend.
Press Release
Articles on Incyte Corp
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers